A Look at BeOne Medicines (ONC) Valuation Following Breakthrough FDA and Project Orbis Milestones

BeOne Medicines (NasdaqGS:ONC) announced that its investigational drug sonrotoclax has received Breakthrough Therapy Designation from the U.S. FDA for relapsed or refractory mantle cell lymphoma. This ...